Ingen Technologies, Inc. engages in the manufacture of respiratory medical devices. The company is headquartered in Riverside, California. The company went IPO on 2001-07-11. The firm holds the manufacturing and marketing platforms to produce its core medical product line, referred to as Oxyview and Smart Nasal Cannula. The firm develops products for the treatment of chronic obstructive pulmonary disease (COPD), such as chronic bronchitis, emphysema and asthmatic bronchitis, all of which obstruct airflow from the lungs. The Company’s products include The Smart Nasal Cannula 206NCA (Adult Size), The Smart Nasal Cannula 203NCA (Adult Size), The Smart Nasal Cannula 206NCP (Child Size), The Smart Nasal Cannula 203NCP (Child Size), The Smart Nasal Cannula 206NC (Infant Size), The Smart Nasal Cannula 203NC (Infant Size), Oxyview 203A And Oxyview 206A.
Ingen Technologies Inc 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Ingen Technologies Inc 的收入按细分市场或地理位置如何划分?
Ingen Technologies Inc 最大收入来源是 Specialty Pharmaceutical Products,在最近的收益报告中收入为 37,867,945。就地区而言, United States 是 Ingen Technologies Inc 的主要市场,收入为 35,167,945。